Trial Profile
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Omiganan (Primary)
- Indications Rosacea
- Focus Adverse reactions
- Sponsors Cutanea Life Sciences
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 30 May 2017 This trial was completed in Sweden, according to European Clinical Trials Database.